Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS(A), US-NovoLog®, and EU-NovoRapid®
NCT ID: NCT06492226
Last Updated: 2024-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
54 participants
INTERVENTIONAL
2024-07-30
2024-11-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NKF-INS(A)
Single subcutaneous dose administration over three treatment periods
NKF-INS(A)
Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
EU-NovoRapid®
Single subcutaneous dose administration over three treatment periods
EU-NovoRapid®
Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
US-NovoLog®
Single subcutaneous dose administration over three treatment periods
US-NovoLog®
Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NKF-INS(A)
Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
EU-NovoRapid®
Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
US-NovoLog®
Single subcutaneous dose of 0.3 U/kg administration over three treatment periods
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Healthy male participants
3. Age between 18 and 50 years, both inclusive
4. Body Mass Index between 18.5 and 29.0 kg/m2, both inclusive
5. Body weight ≥ 50 kg
6. Fasting plasma glucose concentration ≤ 5.5 mmol/L at screening
7. Considered generally healthy upon completion of medical history, physical examination, vital signs, electrocardiogram (ECG), and analysis of laboratory safety variables, as judged by the Investigator
8. Willing and able to comply with scheduled visits, treatment plan, clinical laboratory tests, and other study procedures including lifestyle considerations.
9. Participants must agree to use condoms during sexual intercourse. Additionally, female partners of male participants should use highly effective contraception. All contraceptive measures apply from screening until 90 days after study
10. Have competence in speaking, writing, and comprehending the local language(s) where the study is conducted.
Exclusion Criteria
2. Are currently enrolled in or have discontinued within 3 months or 5 half-lives (whichever is longer) of any investigational drug or device or are concurrently enrolled in any other type of medical research study and judged not to be scientifically or medically compatible with this study.
3. Have known allergies to insulin, its excipients, or related drugs or have history of relevant allergic reactions of any origin.
4. History of diabetes mellitus; episodes of hypoglycemia in the anamnesis; any history of insulin use for treatment purposes.
5. Have known allergies to insulin, its excipients, or related drugs or have history of relevant allergic reactions of any origin.
6. Have clinically relevant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study drug; or of interfering with the interpretation of data.
7. Increased risk of thrombosis, e.g., individuals with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.
8. Clinically significant abnormal ECG at screening.
9. Glycemia level ≥140.4 mg/dL 2 hours after the glucose load.
10. Show evidence of significant active neuropsychiatric disease.
11. Positive urine drug test at screening and/or evidence of current use of known drugs of abuse or have a history of use within the past year.
12. Show evidence of an acute infection with fever or infectious disease at the time of enrollment.
13. Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies at screening.
14. Have positive test results for hepatitis B surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc), or hepatitis C virus (HCV) antibodies at screening.
15. Intend to use over-the-counter medication within 7 days or prescription medication within 14 days prior to dosing (apart from vitamin/mineral supplements, occasional paracetamol, thyroid replacement).
16. Have donated blood or had a blood loss of 450 mL 3 months prior to study enrollment.
17. Have an average weekly alcohol intake that exceeds 21 units per week or is unwilling to stop alcohol consumption from 48 hours prior to each dosing until being discharged from the CRU.
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xentria, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xentria Investigative Site
Bloemfontein, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NKF-INS(A)-101
Identifier Type: -
Identifier Source: org_study_id